NCT06137703 - A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 24, 2022

Primary Completion Date

December 7, 2022

Study Completion Date

December 7, 2022

Conditions

Biological Availability

Interventions

DRUG

Zavegepant 100mg non-enteric coated soft gel capsule

Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule

DRUG

Zavegepant 100mg immediate release tablet

Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet

DRUG

Zavegepant 2 x 100mg immediate release tablets

2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg

DRUG

Zavegepant 4 x 25mg enteric coated soft gel capsule

Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg

Trial Locations (1)

Syneos Health Clinical Research Services, Llc, Miami